Investor Relations Home
Due to an error by our third-party webcasting provider, the live webcast on August 9 was disconnected for approximately three minutes during the Q&A segment. However, the complete webcast is available for replay on demand.
Here you will find financial reports and shareholder information about Omeros Corporation, including recent news, current and historical share price, and electronic copies of our SEC filings.
|Recent Press Releases||More >>|
|Date||Title|| || |
|03/16/17||Omeros Corporation Reports Fourth Quarter and Year-End 2016 Financial Results|
|-- Conference Call Today at 4:30 p.m. ET --
SEATTLE--(BUSINESS WIRE)--Mar. 16, 2017--
Omeros Corporation (NASDAQ: OMER), a biopharmaceutical company committed
to discovering, developing and commercializing both small-molecule and
protein therapeutics for large-market as well as orphan indications
targeting inflammation, coagulopathies and disorders of the central
nervous system, today announced recent highlights and developments as
well as fin... || |
|03/10/17||Omeros Corporation to Announce Fourth Quarter and Year-End 2016 Financial Results on March 16, 2017|
|SEATTLE--(BUSINESS WIRE)--Mar. 10, 2017--
Omeros Corporation (NASDAQ: OMER), today announced that the company will
issue its fourth quarter and year-end 2016 financial results for the
period ended December 31, 2016, on Thursday, March 16, 2017, after the
market closes. Omeros management will host a conference call and webcast
that day at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time) to discuss
the financial results.
Conference Call Detai... || |
|03/02/17||Omeros to Present at the Cowen and Company Annual Health Care Conference|
|SEATTLE--(BUSINESS WIRE)--Mar. 2, 2017--
Omeros Corporation (NASDAQ: OMER) today announced that Gregory A.
Demopulos, M.D., chairman and chief executive officer, will present at
the Cowen and Company 37th Annual Health Care Conference in
Boston, MA next week. The presentation is scheduled for Tuesday, March
7, 2017 at 10:40 a.m. EST.
The presentation will be webcast. The live and archived webcasts can be
accessed on the “Events” page of th... || |
|03/01/17||Omeros Reports Additional Positive Results from OMS721 Phase 2 Trial in Patients with Stem Cell Transplant-Associated Thrombotic Microangiopathy|
|--Data Presented at the Recent Combined International and American
Blood & Marrow Transplantation Meetings--
SEATTLE--(BUSINESS WIRE)--Mar. 1, 2017--
Omeros Corporation (NASDAQ: OMER) today announced additional positive
data from the ongoing Phase 2 clinical trial evaluating OMS721 in the
treatment of hematopoietic stem cell transplant-associated thrombotic
microangiopathy (HCT-TMA). These data were presented at the combined
annual meeting... || |
|There are currently no events scheduled.|
Receive E-mail Alerts|
|Sign up to receive e-mail alerts whenever Omeros Corporation posts new information to the site. Just enter your e-mail address and click Submit.|
Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.